Shopping Cart
Remove All
Your shopping cart is currently empty
WJH-C19
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T217831 Copy Product Info
🥰Excellent
WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. It suppresses the RIPK1/RIPK3/MLKL signaling pathway by blocking RIPK1 phosphorylation and inhibiting downstream phosphorylation of RIPK3 and MLKL, thereby disrupting necrosome formation and demonstrating protective effects against necroptosis (Apoptosis) across various cell lines. In a mouse model of colitis, WJH-C19 alleviates inflammatory bowel disease symptoms by modulating the necroptosis pathway. It also reduces inflammation and bone destruction in a rheumatoid arthritis mouse model. WJH-C19 is relevant for research on inflammatory bowel disease and rheumatoid arthritis.
WJH-C19
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Storage & Solubility Information
| Description | WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. It suppresses the RIPK1/RIPK3/MLKL signaling pathway by blocking RIPK1 phosphorylation and inhibiting downstream phosphorylation of RIPK3 and MLKL, thereby disrupting necrosome formation and demonstrating protective effects against necroptosis (Apoptosis) across various cell lines. In a mouse model of colitis, WJH-C19 alleviates inflammatory bowel disease symptoms by modulating the necroptosis pathway. It also reduces inflammation and bone destruction in a rheumatoid arthritis mouse model. WJH-C19 is relevant for research on inflammatory bowel disease and rheumatoid arthritis. |
| Targets & IC50 | RIPK1:5.7 nM |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags:
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.